. 2018 Mar 25;9(5):606–612. doi: 10.1111/1759-7714.12626

Table 1.

General characteristics of the 15 included publications

Study	No. of patients	Clinical stages	Dosage	Quality of life standard	Results	Time(year)
Study	NPE/NP	Clinical stages	Dosage	Quality of life standard	Results	Time(year)
Yang et al.9	54/33	III,IV	7.5 mg/m², day1–14	ECOG	ORR, adverse reaction	2002–2003
Sun et al.20	322/164	III,IV	15 mg/day, day1–14	ECOG	ORR, adverse reaction	2003–2004
Huang et al.12	50/24	III,IV	7.5 mg/m², day1–14	NR	ORR	2005
Huang10	20/20	III,IV	15 mg/day, day1–14	KPS	ORR, survival, adverse reaction	2006–2007
Fan et al.13	20/20	III,IV	7.5 mg/m², day1–14	KPS	ORR, adverse reaction	2006–2007
Cai et al.11	39/32	III,IV	15 mg/day, day1–14	KPS	ORR, survival, adverse reaction	2006–2007
Wen et al.9	43/41	Advanced	7.5 mg/m², day1–14	KPS	ORR, adverse reaction	2007–2010
Yang et al.14	13/18	IIIb,IV	15 mg/day, day1–14	KPS	ORR, adverse reaction	2006–2008
Wang et al.15	17/18	IIIb,IV	7.5 mg/m², day1–14	ECOG	ORR, survival, adverse reaction	NR
Yang4	60/38	III,IV	15 mg/day, day1–14	NR	ORR, adverse reaction	2008–2012
Liu et al.5	38/34	III,IV	7.5 mg/m², day1–14	ECOG	ORR, survival	2007–2009
Zhang et al.6	20/8	III,IV	7.5 mg/m², day1–14	ECOG	ORR, survival	2009
Wang et al.16	14/17	IIIb,IV	15 mg/day, day1–14	ECOG	ORR, survival, adverse reaction	2007–2008
Guet al.17	26/26	IIIb,IV	7.5 mg/m², day1–14	ECOG	ORR, survival, adverse reaction	2005–2008
Guo & Hu18	16/30	IIIb,IV	15 mg/day, day1–14	KPS	ORR, adverse reaction	2006–2009

ECOG, Eastern Cooperative Oncology Group; KFS, Karnovsky Performance Status; ORR, objective response rate; NP, vinorelbine plus cisplatin; NPE Endostatin + NP; NR, not reported.